Advances in molecular biology, RNA-based therapies, and gene editing could offer new solutions to overcome drug resistance thanks to the development of (i) small interfering RNAs and microRNAs targeting key oncogenic pathways implicated in resistance mechanisms, (ii) long non-coding RNAs (lncRNAs) influencing melanoma progression and therapy resistance, and (iii) CRISPR-based genome editing to correct resistance-associated mutations in genes such as BRAF, MEK, or NRAS [166,167,168]. This evidence concerns the gene BRAF and melanoma.